What do systematic reviews say?

Irinotecan‐based regimens vs irinotecan

Irinotecan‐based regimens showed no clear difference in severe adverse effects compared with irinotecan (moderate certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  RR 1.18 [0.96, 1.45]
  6 studies · 2510 participants
  Moderate

Irinotecan‐based regimens vs irinotecan

Irinotecan‐based regimens probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.68 [0.6, 0.76]
  6 studies · 2615 participants
  Moderate

Intralesional triamcinolone vs Intralesional triamcinolone plus salvianolic acid B

It is very uncertain whether intralesional triamcinolone changes maximal mouth opening (interincisal distance) compared with intralesional triamcinolone plus salvianolic acid B (very low certainty).

• Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes

  More than 6 months
  MD -2.38 [-5.64, 0.88]
  1 study · 28 participants
  Very low

Intralesional triamcinolone vs Intralesional triamcinolone plus salvianolic acid B

It is very uncertain whether intralesional triamcinolone changes burning sensation (VAS 0-100) compared with intralesional triamcinolone plus salvianolic acid B (very low certainty).

• Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes

  Less than 3 months
  MD -1.00 [-10.37, 8.37]
  1 study · 28 participants
  Very low
• Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes

  3 to 6 months
  MD -16.30 [-28.15, -4.45]
  1 study · 28 participants
  Very low

Fibrinolytics vs placebo

Fibrinolytics showed no clear difference in mortality. compared with placebo (moderate certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 1.16 [0.71, 1.91]
  8 studies · 867 participants
  Moderate

Fibrinolytics vs placebo

Fibrinolytics may leads to lower referral for thoracic surgery. compared with placebo (low certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 0.37 [0.21, 0.68]
  8 studies · 897 participants
  Low

Fibrinolytics vs placebo

Fibrinolytics showed no clear difference in serious adverse events compared with placebo (low certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 1.28 [0.36, 4.57]
  9 studies · 935 participants
  Low

Aminophylline vs placebo

Aminophylline showed no clear difference in PEF (L/min) ‐ at 60 min compared with placebo (low certainty).

• Addition of intravenous aminophylline to inhaled beta₂‐agonists in adults with acute asthma 2012 · Cochrane Headline outcomes only
  MD 6.24
  6 studies · 302 participants
  Low

Aminophylline vs placebo

Aminophylline showed no clear difference in hospital admissions compared with placebo (moderate certainty).

• Addition of intravenous aminophylline to inhaled beta₂‐agonists in adults with acute asthma 2012 · Cochrane Headline outcomes only
  OR 0.58 [0.3, 1.12]
  6 studies · 315 participants
  Moderate

Aminophylline vs placebo

Aminophylline showed no clear difference in tremor compared with placebo (low certainty).

• Addition of intravenous aminophylline to inhaled beta₂‐agonists in adults with acute asthma 2012 · Cochrane Headline outcomes only
  OR 2.6 [0.62, 11.02]
  5 studies · 249 participants
  Low

Aminophylline vs placebo

Aminophylline probably leads to higher vomiting compared with placebo (moderate certainty).

• Addition of intravenous aminophylline to inhaled beta₂‐agonists in adults with acute asthma 2012 · Cochrane Headline outcomes only
  OR 4.21 [2.2, 8.07]
  7 studies · 321 participants
  Moderate

Aminophylline vs placebo

Aminophylline probably leads to higher arrhythmia/palpitations compared with placebo (moderate certainty).

• Addition of intravenous aminophylline to inhaled beta₂‐agonists in adults with acute asthma 2012 · Cochrane Headline outcomes only
  OR 3.02 [1.15, 7.9]
  6 studies · 249 participants
  Moderate

Aminophylline vs placebo

• Addition of intravenous aminophylline to inhaled beta₂‐agonists in adults with acute asthma 2012 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Moderate

Irinotecan + targeted therapy vs irinotecan

Irinotecan + targeted therapy showed no clear difference in overall survival compared with irinotecan (low certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.99 [0.88, 1.1]
  2 studies · 1758 participants
  Low

Irinotecan + targeted therapy vs irinotecan

Irinotecan + targeted therapy probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  HR 0.71 [0.64, 0.79]
  2 studies · 1758 participants
  Moderate

Irinotecan + targeted therapy vs irinotecan

Irinotecan + targeted therapy leads to higher overall tumour response compared with irinotecan (high certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  RR 3.38 [2.53, 4.52]
  2 studies · 1758 participants
  High

Irinotecan + targeted therapy vs irinotecan

Irinotecan + targeted therapy leads to higher severe adverse effects compared with irinotecan (high certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  RR 1.44 [1.31, 1.59]
  2 studies · 1704 participants
  High

Lesinurad 200 mg plus allopurinol vs placebo plus allopurinol

Lesinurad 200 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).

• Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
  RR 0.4 [0.04, 4.57]
  2 studies · 103 participants
  Moderate

Lesinurad 400 mg plus allopurinol vs placebo plus allopurinol

Lesinurad 400 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).

• Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
  RR 0.79 [0.42, 1.49]
  2 studies · 98 participants
  Moderate

Tilting-type RDP (minor connector design) vs Functional and sanitary RDP designs

• Interventions for replacing missing teeth: partially absent dentition 2012 · Cochrane All outcomes
  Difference in alveolar bone height was not statistically significant (P = 0.07); data narrative only
  1 study · 25 participants
  GRADE not reported